Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPN536 in Advanced Mesothelin-Expressing Cancers
NCT03872206Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Primary completion
- Jan 2023
- Modality
- Antibody Fragments, Antibody-Drug Conjugates (ADCs), Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of HPN536 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 2 more (3 arms), sponsored by Merck & Co. Primary endpoints: Adverse Events at 3 years, Maximum Tolerated Dose / Recommended Phase 2 Dose at 2 years and 1 more. Started Apr 2019; status: completed.
02
Drugs
HPN536
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)pancreatic adenocarcinoma (PDAC)malignant mesothelioma
Beyond the preview
Go deeper on NCT03872206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872206.